[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
M A SoldatovL V KlimovA P TolmachevT V KiselevaO V AndrofaginaE M BeketovaS N BelkinaD N BorisovD Yu KarpovM S KrasyukM V KucheryavayaYu D MininaD G NovikovN V RogozhnikovaS V TabakmanYu A TelyatnikK V TretyakovA S FadeevaD S KhanA N ChirkovN A MarskayaN A ShamalovPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
Performing TLT with the drug Revelisa in patients with AI leads to a statistically significant regression of neurological symptoms. A significant proportion of patients achieve a favorable clinical outcome upon discharge from the hospital and in the long term. The obtained data on the efficacy and safety profile correlate with previously published register studies of alteplase in AI.
Keyphrases
- clinical practice
- end stage renal disease
- artificial intelligence
- adverse drug
- chronic kidney disease
- healthcare
- acute ischemic stroke
- pulmonary embolism
- high dose
- prognostic factors
- electronic health record
- emergency department
- atrial fibrillation
- big data
- randomized controlled trial
- systematic review
- low dose
- drug induced
- patient reported
- blood brain barrier
- subarachnoid hemorrhage